| Duplicates removed | 97 |
| Excluded during initial screening (e.g. press releases; news reports; not relevant drug/indication; preclinical study; reviews; case reports; not randomized trial) | 119 |
| Excluded during writing (e.g. reviews; duplicate data; small patient number; nonrandomized/phase I/II trials) | 23 |
| Cited efficacy/tolerability articles | 31 |
| Cited articles not efficacy/tolerability | 20 |
| Search Strategy: EMBASE, MEDLINE and PubMed from 2016 to present. Previous Adis Drug Evaluation published in 2016 was hand-searched for relevant data. Clinical trial registries/databases and websites were also searched for relevant data. Key words were tiotropium, olodaterol, Spiolto Respimat, Stiolto Respimat, Vehelva Respimat. Records were limited to those in English language. Searches last updated 6 May 2019 | |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.